Abstract Objectives This comprehensive review aims to examine the reciprocal interplay between Type 2 diabetes mellitus (T2DM) and sarcopenia, identify prevailing research gaps, and discuss therapeutic approaches and measures to enhance healthcare practices within hospital settings
Updated April 2024
All content on this page is produced by the Practice Plus Group digital content team and clinically reviewed by consultant specialists to ensure accuracy, patient safety, and alignment with current UK clinical best practice
The 2.0 mg dose was added in 2022 after a phase 3 trial showed additional glycemic benefit
The GLP1R rs6923761 variant significantly influences how strongly your body responds to semaglutide's appetite-suppressing effects
12 By embracing these strategies, individuals using GLP-1 medications can optimize their results, minimize discomfort, and build a foundation for a healthier, more empowered future